A Phase 2 interventional study of Capadenoson (BAY 68-4986) and Capadenoson (BAY 68-4986) in Chronic Stable Angina, sponsored by Bayer. Withdrawn at 36 sites in 6 countries. Open to participants aged 35 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-01-13.
Sponsored by Bayer · Phase 2, Interventional, and Treatment
This is a multi-center and multi-national,randomized, double blind, placebo-controlled, 28-day treatment study with BAY 68-4986 taken orally or a matching placebo.
519 studies on the registry are indexed under Angina Pectoris; 82 are open to participants now.
Browse Angina Pectoris studies →Bayer is the lead sponsor of 1,643 studies on the registry; 57 are open to participants now.
Of its 209 completed or terminated interventional studies of FDA-regulated products, 129 (62%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: Capadenoson (BAY 68-4986)
Drug: Capadenoson (BAY 68-4986)
Drug: Capadenoson (BAY 68-4986)
Drug: Placebo
1mg Capadenoson, double dummy
2mg Capadenoson, double dummy
4mg Capadenoson, double dummy
Placebo, double dummy
Total exercise time
Time frame: 28 days for ETT and 42 days for safety
Time to angina onset
Time frame: 28 days
This study is withdrawn, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bayer